Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2009

View Archived Issues

Reduced fractures with denosumab in postmenopausal women and men with prostate cancer

Studies with HC-056456 reveal CatSper channels as a target for blocking fertility

rAAV1-AAT gene therapy shows promise for future development in phase I trial

Doxorubicin derivative INNO-206 more potent than free doxorubicin in vivo

Merck & Co. to assess safety/efficacy of MK-2578 in kidney disease patients in phase II trial

Safety and efficacy of JTT-130 to be evaluated in obese type 2 diabetic patients

Bayer relegates clinical trials for alemtuzumab to Genzyme Japan

Bevacizumab plus erlotinib therapy shows activity in phase II clinical trial in HCC

Can-Fite BioPharma reports results from its phase II CF-101 trial in psoriasis

Opexa Therapeutics reports additional data with Tovaxin for multiple sclerosis

Novel PARP inhibitors presented by AstraZeneca for cancer therapy

R-Tech Ueno presents VAP-1 inhibitors for macular edema and other eye conditions

Akela undergoes corporate restructuring

PPARgamma agonists for the treatment of AD described by GlaxoSmithKline

Panacea Biotec discloses DPP-IV inhibitors for the treatment of type 2 diabetes

NeuroSearch patents novel dopamine and serotonin receptor ligands as antipsychotics

Luminex receives 510(k) clearance for new cystic fibrosis test

XenoPort reports results from a safety and tolerability trial of arbaclofen

LigoCyte initiates phase I/II study of nasally delivered dry powder norovirus vaccine

Shire provides update on velaglucerase alfa for Gaucher's disease

GlycoMimetics begins pilot study of GMI-1070 in sickle cell patients

Dor BioPharma receives NIH grant to support phase I/II DOR-201 trial in radiation enteritis

Evotec commences phase I trial of EVT-103

Ark Therapeutics receives feedback from MHRA on EG-013

Bayer Schering submits IND for phase I MN-IC trial, triggering milestone payments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...